Myasthenia gravis (MG) is an autoimmune disorder characterized by abnormal neuromuscular transmission. The thymus is believed to play a key role in the pathogenesis of MG, and thymectomy has been an optional treatment for the disease. Exacerbations and new onset of MG following COVID-19 vaccination have also been documented. This report presents a case of a healthy girl with recent COVID-19 vaccination than respiratory failure developed. A 16-year-old previous healthy girl received the first dose of the BNT162b2 mRNA COVID-19 vaccine generalized weakness and respiratory failure developed after 24 hours and he was intubated after 36 hours of vaccination. Complete recovery was observed after IVIG treatment. The patient was discharged with full recovery. She was diagnosed with systemic myasthenia gravis in her second attack 3 months later from first attack. The patient whose attacks continue despite pridostigmine and azathioprine treatments before thymectomy. Post-thymectomy pathology was found to be compatible with thymoma. After thymectomy, the patient had no serious crisis during the 6-month follow-up. In our knowledge, this is the first pediatric systemic myasthenia case whose symptoms started after BNT162b2 vaccination and who diagnosed thymoma during follow-up.

SERKAN KIRIK
Firat University School Of Medicine
Turkey

Mehmet Ağar
Health Sciences University School Of Medicine
Turkey

Yasemin KIRIK
Health Sciences University School Of Medicine
Turkey

Hadice Akyol
Health Sciences University School Of Medicine
Turkey